The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower their blood sugar, this is genuinely good news — and worth pausing to recognize.
What Just Happened
- The FDA greenlit generic formulations of dapagliflozin for Type 2 diabetes this month, opening the door to significantly cheaper monthly prescriptions for a drug that has been a standard part of the ADA Standards of Care tool kit for nearly a decade.
- Dapagliflozin works in the kidneys — it blocks reabsorption of glucose and lets excess sugar leave the body through urine, lowering fasting and post-meal blood sugar in adults with Type 2 diabetes.
- Beyond glucose control, the drug class has earned an outsized reputation for cardiorenal protection — reducing hospitalizations for heart failure and slowing the progression of chronic kidney disease in patients with and without diabetes.
- The clinical trial history is strong. The original DECLARE-TIMI 58 cardiovascular outcomes trial enrolled more than 17,000 adults and helped position SGLT2 inhibitors as a first-line consideration for many patients with Type 2 diabetes who have cardiovascular or kidney risk.
- Generic approval is a commercial event more than a scientific one. The molecule is the same. The mechanism is the same. The prescription experience is the same. What changes is price, and that is a real, material win for patients paying out of pocket.
- Coverage decisions from major payers and pharmacy benefit managers are expected to follow within 60 to 90 days. Watch for shifts in formulary tier and the disappearance of brand-tier copays at the counter.
A Different Question to Sit With
Dapagliflozin is a good drug. SGLT2 inhibitors are a good drug class. The clinical trial record is deep, the side-
effect profile is well understood, and the cardiorenal story is genuinely impressive. None of that is in dispute, and none of it should be in order to raise a separate question worth sitting with.
That question is: what is the goal?
The dominant conversation around a generic approval like this is, appropriately, about who gets easier access to a medication that lowers their blood sugar and protects their heart and kidneys. It is a conversation about better management — a meaningful and legitimate conversation that millions of adults with Type 2 diabetes benefit from every day.
It is also a conversation that takes the endpoint as given. The endpoint is medication. The endpoint is the daily pill, the refilled prescription, the lab draw that confirms the A1c is in target, the next visit that confirms it is still in target, the next generic that makes the next refill a little easier. There is nothing wrong with that pathway for patients who need it. There is a great deal right with it.
There is a different endpoint available to a meaningful subset of adults with Type 2 diabetes, and it has been documented in the peer-reviewed clinical literature for over a decade. That endpoint is reversal — an A1c of 6.4% or lower, sustained, with every diabetes medication discontinued. The research out of Newcastle University, the DiRECT trial published in The Lancet, and the 2021 ADA/EASD/Diabetes UK/Endocrine Society consensus statement on remission all describe the same underlying finding: significant, structured nutritional intervention early in the disease can restore beta-cell function, normalize blood sugar, and take patients off glucose-lowering medication entirely. Not for everyone. Not guaranteed. But real, and reproducible inside a structured Type 2 diabetes reversal protocol.
Both paths deserve to be on the table. The patient demand for actual reversal is real and growing. The constraint has been that the standard care pathway hasn’t historically offered it as a first-line option.
What Reversal Actually Looks Like
Reversal means something specific. It means an A1c of 6.4% or lower, with every diabetes medication discontinued, sustained over time. At Diabetes Reversal Group, that is the only metric we track.
The source of truth for our clinical results is an independent review of 137 participants who completed the program between 2013 and 2021. The data: an average post-program A1c of 6.04%, an average time in the program of 4.5 months. To date, the program has been delivered to thousands of adults with Type 2 diabetes, and the patient outcomes on our testimonial page reflect what that protocol looks like in practice — adults who came in on metformin, on SGLT2 inhibitors, on insulin, and who walked out with a stopped prescription list and an A1c back below the diabetic threshold.
That outcome is not a research curiosity. It is a daily clinical reality for the patients who pursue it.
The Bottom Line
Generic dapagliflozin is a real win. For the millions of adults currently taking an SGLT2 inhibitor, lower-cost refills and broader formulary access are material improvements to the day-to-day experience of managing Type 2 diabetes. The science behind the drug class is sound, the cardiorenal story is real, and the ADA Standards of Care have good reasons to keep it as a first-line consideration for many patients.
If your goal is management, those are real wins. If your goal is reversal of Type 2 diabetes, there is a different
path, with a different evidence base, and a different conversation to have with your care team. The free reversal webinar walks through the protocol, the independent study data, and the patient selection criteria so you can decide whether it fits your situation. Both paths deserve to be on the table. The patients who do best are the ones who know both exist.
By:
Dr. Jeffrey Hockings
Co-Founder/CEO
Diabetes Reversal Group
Kristine Burke, MD
Chief Medical Officer
Diabetes Reversal Group